Posters
(results will display both Free Papers & Poster)
Phakic implantable collamer lens for moderate to high myopia and astigmatism: clinical outcomes of the V4C model
Poster Details
First Author: J.Ferreira Mendes PORTUGAL
Co Author(s): J. Pires T. Monteiro N. Franqueira F. Faria-Correia F. Vaz
Abstract Details
Purpose:
To assess the safety, efficacy, predictability and stability following the use of a posterior chamber phakic implantable collamer lens V4C (Visian ICL, STAAR Surgical Co) in patients with moderate to high myopia and astigmatism.
Setting:
Ophthalmology department, Hospital de Braga, Portugal
Methods:
This retrospective study evaluated 43 eyes of 25 patients who underwent ICL implantation (V4c model).25 eyes were implanted with a spherical ICL while 18 eyes were implanted with a toric ICL. Complete ophthalmologic examination was perfomed before surgery and at 1, 6 and 12 months. Lens power was calculated based on subjective refraction, anterior chamber depth (ACD) and keratometric measurements obtained by corneal topography (Pentacam® HR, Oculus). Horizontal and vertical angle-to-angle distance was measured with optical coherence tomography (OCT Visante Omni®, Carl Zeiss Meditec), using these results to calculate the lens diameter.
Results:
Mean spherical equivalent refraction after a 6 months follow-up improved from -6,48 ± 3,49 D to 0,22 ± 0,41 D, with an uncorrected distance visual acuity of 0,88 ± 0,18. Change in manifest refraction from week 1 to month 6 was insignificant. 12 months after surgery 93% of eyes were within ± 0,50 D of the targeted correction and 100% were within ± 1,00 D. Average vault was 521,6 ± 332,5 μm. No significant rise in intraocular pressure or secondary cataract occurred in any case during the period of observation.
Conclusions:
This retrospective analysis demonstrates that ICL implantation for moderate to high myopia and astigmatism is safe and effective, with predictable refractive results, suggesting its viability as a surgical option for the treatment of such eyes.
Financial Disclosure:
NONE